Collagen VII Half-Life at the Dermal-Epidermal Junction Zone: Implications for Mechanisms and Therapy of Genodermatoses

Journal of Investigative Dermatology

Volumn 136, Issue 6, 2016, Pages 1116-1123

  Kühl, Tobias ^a   Mezger, Markus ^b   Hausser, Ingrid ^c   Guey, Lin T ^d   Handgretinger, Rupert ^b   Bruckner Tuderman, Leena ^a   Nyström, Alexander ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^c UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^d SHIRE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN TYPE 7; TAMOXIFEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; DERMOEPIDERMAL JUNCTION; EPIDERMOLYSIS BULLOSA DYSTROPHICA; GENETIC DISORDER; GENODERMATOSIS; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; ANIMAL; BIOLOGICAL THERAPY; CELL CULTURE; CYTOLOGY; DERMIS; DISEASE MODEL; EPIDERMIS; FIBROBLAST; GENE THERAPY; GENETICS; HALF LIFE TIME; HUMAN; KNOCKOUT MOUSE; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; METABOLISM; PROCEDURES; RANDOMIZATION; SKIN DISEASES, GENETIC; WESTERN BLOTTING;

ANIMALS; BLOTTING, WESTERN; CELL- AND TISSUE-BASED THERAPY; CELLS, CULTURED; COLLAGEN TYPE VII; DERMIS; DISEASE MODELS, ANIMAL; EPIDERMIS; EPIDERMOLYSIS BULLOSA DYSTROPHICA; FIBROBLASTS; GENETIC THERAPY; HALF-LIFE; HUMANS; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; MICE; MICE, KNOCKOUT; RANDOM ALLOCATION; SKIN DISEASES, GENETIC;

EID: 84977266815     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1016/j.jid.2016.02.002     Document Type: Article

References (38)

1. Alexeev, V., Uitto, J., Igoucheva, O., Gene expression signatures of mouse bone marrow-derived mesenchymal stem cells in the cutaneous environment and therapeutic implications for blistering skin disorder. Cytotherapy 13 (2011), 30–45.
2. Amano, S., Ogura, Y., Akutsu, N., Matsunaga, Y., Kadoya, K., Adachi, E., et al. Protective effect of matrix metalloproteinase inhibitors against epidermal basement membrane damage: skin equivalents partially mimic photoageing process. Br J Dermatol 153:Suppl. 2 (2005), 37–46.
3. Behrens, D.T., Villone, D., Koch, M., Brunner, G., Sorokin, L., Robenek, H., et al. The epidermal basement membrane is a composite of separate laminin- or collagen IV-containing networks connected by aggregated perlecan, but not by nidogens. J Biol Chem 287 (2012), 18700–18709.
4. Belle, A., Tanay, A., Bitincka, L., Shamir, R., O'Shea, E.K., Quantification of protein half-lives in the budding yeast proteome. Proc Natl Acad Sci USA 103 (2006), 13004–13009.
5. Bruckner-Tuderman, L., Schnyder, U.W., Winterhalter, K.H., Bruckner, P., Tissue form type VII collagen from human skin and dermal fibroblasts in culture. Eur J Biochem 165 (1987), 607–611.
6. Cambridge, S.B., Gnad, F., Nguyen, C., Bermejo, J.L., Kruger, M., Mann, M., Systems-wide proteomic analysis in mammalian cells reveals conserved, functional protein turnover. J Proteome Res 10 (2011), 5275–5284.
7. Carulli, S., Contin, R., De Rosa, L., Pellegrini, G., De Luca, M., The long and winding road that leads to a cure for epidermolysis bullosa. Regen Med 8 (2013), 467–481.
8. Chung, H.J., Uitto, J., Type VII collagen: the anchoring fibril protein at fault in dystrophic epidermolysis bullosa. Dermatol Clin 28 (2010), 93–105.
9. Compton, C.C., Current concepts in pediatric burn care: the biology of cultured epithelial autografts: an eight-year study in pediatric burn patients. Eur J Pediatr Surg 2 (1992), 216–222.
10. Fine, J.D., Johnson, L.B., Weiner, M., Li, K.P., Suchindran, C., Epidermolysis bullosa and the risk of life-threatening cancers: The National EB Registry experience, 1986-2006. J Am Acad Dermatol 60 (2009), 203–211.
11. Fritsch, A., Loeckermann, S., Kern, J.S., Braun, A., Bosl, M.R., Bley, T.A., et al. A hypomorphic mouse model of dystrophic epidermolysis bullosa reveals mechanisms of disease and response to fibroblast therapy. J Clin Invest 118 (2008), 1669–1679.
12. Georgiadis, C., Syed, F., Petrova, A., Abdul-Wahab, A., Lwin, S.M., Farzaneh, F., et al. Lentiviral engineered fibroblasts expressing codon optimized COL7A1 restore anchoring fibrils in RDEB. J Invest Dermatol 136 (2016), 284–292.
13. Has, C., Bruckner-Tuderman, L., The genetics of skin fragility. Annu Rev Genomics Hum Genet 15 (2014), 245–268.
14. Heintz, B., Stöcker, G., Mrowka, C., Rentz, U., Melzer, H., Stickeler, E., et al. Decreased glomerular basement membrane heparan sulfate proteoglycan in essential hypertension. Hypertension 25 (1995), 399–407.
15. Hernández-Pérez, M., Mahalingam, M., Matrix metalloproteinases in health and disease: insights from dermatopathology. Am J Dermatopathol 34 (2012), 565–579.
16. Hou, Y., Guey, L.T., Wu, T., Gao, R., Cogan, J., Wang, X., et al. Intravenously administered recombinant human type VII collagen derived from Chinese hamster ovary cells reverses the disease phenotype in recessive dystrophic epidermolysis bullosa mice. J Invest Dermatol 135 (2015), 3060–3067.
17. Iriyama, S., Tsunenaga, M., Amano, S., Adachi, E., Key role of heparan sulfate chains in assembly of anchoring complex at the dermal-epidermal junction. Exp Dermatol 20 (2011), 953–955.
18. Kerkelä, E., Saarialho-Kere, U., Matrix metalloproteinases in tumor progression: focus on basal and squamous cell skin cancer. Exp Dermatol 12 (2003), 109–125.
19. Kern, J.S., Loeckermann, S., Fritsch, A., Hausser, I., Roth, W., Magin, T.M., et al. Mechanisms of fibroblast cell therapy for dystrophic epidermolysis bullosa: high stability of collagen VII favors long-term skin integrity. Mol Ther 17 (2009), 1605–1615.
20. Kuhl, T., Mezger, M., Hausser, I., Handgretinger, R., Bruckner-Tuderman, L., Nystrom, A., High local concentrations of intradermal MSCs restore skin integrity and facilitate wound healing in dystrophic epidermolysis bullosa. Mol Ther 23 (2015), 1368–1379.
21. Muir, A.M., Ren, Y., Butz, D.H., Davis, N.A., Blank, R.D., Birk, D.E., et al. Induced ablation of Bmp1 and Tll1 produces osteogenesis imperfecta in mice. Hum Mol Genet 23 (2014), 3085–3101.
22. Nystrom, A., Thriene, K., Mittapalli, V., Kern, J.S., Kiritsi, D., Dengjel, J., et al. Losartan ameliorates dystrophic epidermolysis bullosa and uncovers new disease mechanisms. EMBO Mol Med 7 (2015), 1211–1228.
23. Nystrom, A., Velati, D., Mittapalli, V.R., Fritsch, A., Kern, J.S., Bruckner-Tuderman, L., Collagen VII plays a dual role in wound healing. J Clin Invest 123 (2013), 3498–3509.
24. Petrof, G., Lwin, S.M., Martinez-Queipo, M., Abdul-Wahab, A., Tso, S., Mellerio, J.E., et al. Potential of systemic allogeneic mesenchymal stromal cell therapy for children with recessive dystrophic epidermolysis bullosa. J Invest Dermatol 135 (2015), 2319–2321.
25. Price, R.G., Spiro, R.G., Studies on the metabolism of the renal glomerular basement membrane. Turnover measurements in the rat with the use of radiolabeled amino acids. J Biol Chem 252 (1977), 8597–8602.
26. Prox, J., Arnold, P., Becker-Pauly, C., Meprin α and meprin β: procollagen proteinases in health and disease. Matrix Biol 44-46 (2015), 7–13.
27. Raghunath, M., Hopfner, B., Aeschlimann, D., Luthi, U., Meuli, M., Altermatt, S., et al. Cross-linking of the dermo-epidermal junction of skin regenerating from keratinocyte autografts. Anchoring fibrils are a target for tissue transglutaminase. J Clin Invest 98 (1996), 1174–1184.
28. Rattenholl, A., Pappano, W.N., Koch, M., Keene, D.R., Kadler, K.E., Sasaki, T., et al. Proteinases of the bone morphogenetic protein-1 family convert procollagen VII to mature anchoring fibril collagen. J Biol Chem 277 (2002), 26372–26378.
29. Remington, J., Wang, X., Hou, Y., Zhou, H., Burnett, J., Muirhead, T., et al. Injection of recombinant human type VII collagen corrects the disease phenotype in a murine model of dystrophic epidermolysis bullosa. Mol Ther 17 (2009), 26–33.
30. Schwanhäusser, B., Busse, D., Li, N., Dittmar, G., Schuchhardt, J., Wolf, J., et al. Global quantification of mammalian gene expression control. Nature 473 (2011), 337–342.
31. Schwieger-Briel, A., Weibel, L., Chmel, N., Leppert, J., Kernland-Lang, K., Gruninger, G., et al. A COL7A1 variant leading to in-frame skipping of exon 15 attenuates disease severity in recessive dystrophic epidermolysis bullosa. Br J Dermatol 173 (2015), 1308–1311.
32. Urich, D., Eisenberg, J.L., Hamill, K.J., Takawira, D., Chiarella, S.E., Soberanes, S., et al. Lung-specific loss of the laminin α3 subunit confers resistance to mechanical injury. J Cell Sci 124 (2011), 2927–2937.
33. Vadon-Le Goff, S., Hulmes, D.J.S., Moali, C., BMP-1/tolloid-like proteinases synchronize matrix assembly with growth factor activation to promote morphogenesis and tissue remodeling. Matrix Biol 44-46 (2015), 14–23.
34. Vanden Oever, M., Tolar, J., Advances in understanding and treating dystrophic epidermolysis bullosa. F1000Prime Rep, 6, 2014, 35.
35. Verzijl, N., DeGroot, J., Thorpe, S.R., Bank, R.A., Shaw, J.N., Lyons, T.J., et al. Effect of collagen turnover on the accumulation of advanced glycation end products. J Biol Chem 275 (2000), 39027–39031.
36. Villone, D., Fritsch, A., Koch, M., Bruckner-Tuderman, L., Hansen, U., Bruckner, P., Supramolecular interactions in the dermo-epidermal junction zone: anchoring fibril-collagen VII tightly binds to banded collagen fibrils. J Biol Chem 283 (2008), 24506–24513.
37. Waterlow, J.C., Protein turnover with special reference to man. Q J Exp Physiol Camb Engl 69 (1984), 409–438.
38. Watt, S.A., Dayal, J.H., Wright, S., Riddle, M., Pourreyron, C., McMillan, J.R., et al. Lysyl hydroxylase 3 localizes to epidermal basement membrane and is reduced in patients with recessive dystrophic epidermolysis bullosa. PLoS One, 10, 2015, e0137639.